Pages that link to "Q38163448"

The following pages link to Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design (Q38163448):

Displaying 43 items.

• Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study (Q27300707) (← links)
• Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study (Q27313352) (← links)
• Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010. (Q27318158) (← links)
• Developments in HIV-1 immunotherapy and therapeutic vaccination. (Q30364312) (← links)
• Disclosure of pharmacokinetic drug results to understand nonadherence (Q30674432) (← links)
• Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence (Q33765789) (← links)
• Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission (Q34034418) (← links)
• ARV-based HIV prevention for women - where we are in 2014. (Q34180729) (← links)
• Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures (Q34675000) (← links)
• Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial (Q35561492) (← links)
• Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis (Q35746114) (← links)
• Rethinking HIV prevention to prepare for oral PrEP implementation for young African women (Q35875710) (← links)
• Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria. (Q36057387) (← links)
• Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066) (Q36406923) (← links)
• Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women (Q36443803) (← links)
• The promise and pitfalls of long-acting injectable agents for HIV prevention (Q36561375) (← links)
• Nondaily preexposure prophylaxis for HIV prevention (Q36669377) (← links)
• Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice (Q36710299) (← links)
• Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1. (Q37126494) (← links)
• Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women (Q37224902) (← links)
• Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study (Q37341579) (← links)
• Using Digital Technologies in Clinical HIV Research: Real-World Applications and Considerations for Future Work. (Q38649106) (← links)
• Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence (Q38849535) (← links)
• Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State (Q39488863) (← links)
• Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice (Q40062702) (← links)
• Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial (Q40084752) (← links)
• Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men. (Q40292568) (← links)
• Evaluation of Sexual Risk Behavior Among Study Participants in the TDF2 PrEP Study Among Heterosexual Adults in Botswana (Q40581358) (← links)
• Non-human primate models of hormonal contraception and HIV. (Q42225882) (← links)
• PrEP Implementation Science: State-of-the-Art and Research Agenda (Q43241737) (← links)
• Adolescent pre-exposure prophylaxis for HIV prevention: current perspectives (Q46540207) (← links)
• Women and ARV-based prevention: opportunities and challenges (Q46553256) (← links)
• Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model (Q46843041) (← links)
• Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy. (Q47377243) (← links)
• Evaluating the impact of DREAMS on HIV incidence among young women who sell sex: protocol for a non-randomised study in Zimbabwe. (Q47550891) (← links)
• Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05). (Q50028271) (← links)
• Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. (Q53681301) (← links)
• Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice. (Q53837345) (← links)
• HIV Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline Promise (Q59352978) (← links)
• Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis (Q64235564) (← links)
• Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema (Q88869972) (← links)
• Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa (Q92213693) (← links)
• Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa (Q92641307) (← links)